Canyon Labs, a global leader in analytical and packaging lab testing for medical devices and pharmaceuticals, has announced the acquisition of iuvo BioScience's laboratory services and scientific consulting divisions. This move bolsters Canyon Labs’s capacity to deliver end-to-end solutions for pharmaceutical and medical device development, while allowing iuvo BioScience to focus exclusively on ophthalmic clinical research services, the company said in a press release.

The acquisition will integrate iuvo’s laboratory and consulting teams into Canyon Labs’ operations, enhancing its capabilities in rapid sterility testing, biocompatibility, microbiology, and analytical chemistry. “This acquisition represents a significant milestone for Canyon Labs as we enhance our capacity and expertise,” said Sarah Ptach, president of Canyon Labs. “By uniting our organizations, we are positioned to deliver unparalleled service and innovation to our clients globally.”

For iuvo BioScience, this strategic realignment underscores its commitment to advancing ophthalmic clinical research. “This decision sharpens our focus on accelerating access to breakthrough vision care treatments,” said Ben Burton, president and CEO of iuvo BioScience.